Pfizer Inc. (NYSE:PFE) Shares Acquired by Philip James Wealth Mangement LLC

Philip James Wealth Mangement LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 3.4% in the first quarter, HoldingsChannel.com reports. The firm owned 331,466 shares of the biopharmaceutical company’s stock after acquiring an additional 11,035 shares during the period. Pfizer accounts for approximately 1.0% of Philip James Wealth Mangement LLC’s investment portfolio, making the stock its 18th biggest holding. Philip James Wealth Mangement LLC’s holdings in Pfizer were worth $8,399,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Rialto Wealth Management LLC acquired a new position in Pfizer in the fourth quarter valued at approximately $26,000. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer in the 4th quarter worth about $27,000. Gould Capital LLC boosted its stake in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer in the 4th quarter worth about $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $30,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of Pfizer stock opened at $24.30 on Friday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The stock has a market cap of $138.18 billion, a PE ratio of 17.61, a price-to-earnings-growth ratio of 0.88 and a beta of 0.57. The business has a fifty day simple moving average of $23.42 and a 200-day simple moving average of $24.85.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business’s quarterly revenue was down 7.8% compared to the same quarter last year. During the same period last year, the company posted $0.82 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.08%. Pfizer’s payout ratio is 124.64%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PFE. The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Cantor Fitzgerald initiated coverage on Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 target price on the stock. Finally, Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.